Raquel Ancos-Pintado

Raquel Ancos-Pintado

Auto-generated profile, based on publicly available information

Raquel Ancos-Pintado

Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid, Pl. de Ramón y Cajal s/n, Madrid, 28040, Comunidad de Madrid, Spain; Hematologic Malignancies Clinical Research Unit H12O-CNIO, Department of Hematology, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 de Octubre (imas12), Madrid, 28041, Comunidad de Madrid, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
RGRoberto García-Vicente
Roberto García-Vicente
ARAlba Rodríguez-García
Alba Rodríguez-García
RARaquel Ancos-Pintado
Raquel Ancos-Pintado
AAAndrés Arroyo
Andrés Arroyo
AOAdriana Ortega-Hernández
Adriana Ortega-Hernández
MLMaría Linares
María Linares
Purpose: The microbiota is recognized as an important contributor to the efficacy of immunotherapies. The aim of this study is to analyze the role of gut microbiota and related metabolites in the response of chimeric antigen receptor (CAR) T cells for non-Hodgkin lymphoma. Experimental Design: Stool, serum, and clinical data were collected from 84 patients with non-Hodgkin lymphoma from four hospitals before CD19 CAR T-cell treatment. The microbiota was characterized through 16S rRNA gene sequencing, and serum short-chain fatty acids (SCFA) were measured using mass spectrometry. CAR T cells were exposed to butyrate; their in vitro cytotoxicity was determined, and molecular mechanisms were characterized by flow cytometry and RNA sequencing and then assessed in an in vivo model. Results: As we confirmed the negative impact of antibiotics on the response, we delved into the mechanisms involved. We showed that they reduce microbiota diversity and that their composition correlates with the response. We identified SCFA-producing bacterial groups, including Prevotella, Ruminococcus, and Butyricicoccus, as having a relatively higher abundance in the microbiota of patients who responded to CAR T cells. Analysis of butyrate levels revealed a positive correlation with survival, potentially representing a novel biomarker of response. Finally, we found that stimulation of CAR T cells with butyrate induced phenotypic and transcriptomic changes associated with enhanced antitumor efficacy. Conclusions: Our results support the relationship between microbiota and CAR T-cell therapy major outcomes. Analysis of microbiota led to the identification of SCFAs, especially butyrate, as a prognostic factor, and also provides the basis for considering them as chemical modifiers of CAR T cells to improve their efficacy.

26 May 2026 in Blood Reviews
Verified
Journal Article
Open access
IHIgnacio Hernández-Abad
Ignacio Hernández-Abad
RARaquel Ancos-Pintado
Raquel Ancos-Pintado
AMAna Mendoza
Ana Mendoza
ÁBÁlvaro Basterra-García
Álvaro Basterra-García
RGRoberto García-Vicente
Roberto García-Vicente
MLMaría J. Ledesma-Carbayo
María J. Ledesma-Carbayo
Artificial intelligence (AI) is transforming morphological assessment in hematologic malignancies by enabling automated cell classification, detection of disease-specific features, and prediction of genetic alterations from blood and bone marrow smear images. Deep learning models have achieved expert-level performance in identifying malignant patterns, uncovering morphologic-molecular associations, and providing patient-level diagnoses through multiple instance learning approaches. This review summarizes recent advances in AI-driven morphological analysis across myeloid and lymphoid neoplasms, emphasizing their impact on diagnosis and disease classification. We further examine emerging evidence linking image-derived features, such as nuclear texture, cytoplasmic granularity, and spatial cell organization, to molecular and prognostic variables. In addition, we discuss enabling technologies, including virtual staining and interpretability methods, that support clinical integration. Finally, we address key challenges, including data heterogeneity, the need for prospective validation, and interdisciplinary collaboration. AI-powered, explainable morphological analysis has the potential to advance precision hematology and personalized patient management.